Reducing Systemic Inflammation: A Peptide-Based Approach
article

Reducing Systemic Inflammation: A Peptide-Based Approach

How peptides like BPC-157, KPV, thymosin alpha-1, and LL-37 target systemic inflammation at the molecular level. Evidence-based protocols, mechanisms, and practical guidance.

By PeptideRundown Team •
⚠️ Medical Disclaimer: This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Inflammation · Peptide Protocols

Reducing Systemic Inflammation: A Peptide-Based Approach

Chronic, low-grade inflammation underlies most modern diseases. Here's how specific peptides target the inflammatory cascade at the molecular level, what the research actually shows, and how to build a protocol that works.

Anti-Inflammatory Immune Modulation Cytokine Regulation Evidence-Based
60%
Of Chronic Disease
Linked to Inflammation
6+
Peptides With
Anti-Inflammatory Data
TNF-α
Primary Cytokine
Target
NF-κB
Key Pathway
Modulated

Inflammation isn't inherently bad. It's the body's first response to injury, infection, and tissue damage. Acute inflammation clears pathogens, removes debris, and initiates repair. The problem starts when this response doesn't shut off.

Chronic systemic inflammation is a different animal entirely. It's low-grade, persistent, and often clinically silent for years. By the time it shows up on a standard blood panel as elevated CRP or ESR, it's already been reshaping your tissue environment, driving insulin resistance, accelerating atherosclerosis, and degrading joint cartilage (Furman et al., 2019).

Conventional anti-inflammatory approaches, primarily NSAIDs and corticosteroids, suppress symptoms but carry significant long-term risks: GI bleeding, cardiovascular events, bone density loss, immune suppression. Peptides offer a fundamentally different strategy. Rather than broadly suppressing the immune response, specific peptides modulate inflammatory signaling at precise molecular checkpoints.

What This Guide Covers

This article examines how peptides like BPC-157, KPV, thymosin alpha-1, and LL-37 reduce systemic inflammation through distinct mechanisms. It's an educational overview of the current research, not a prescription. Always consult a qualified healthcare provider before starting any peptide protocol.


Understanding Systemic Inflammation

The inflammatory response follows a well-characterized cascade. Tissue damage or pathogen recognition activates pattern recognition receptors (like Toll-like receptors), which trigger NF-κB translocation to the nucleus. This drives production of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and others. These cytokines recruit immune cells, increase vascular permeability, and amplify the inflammatory signal.

In healthy tissue, resolution pathways kick in within hours to days. Specialized pro-resolving mediators (SPMs), regulatory T cells, and anti-inflammatory cytokines like IL-10 actively dampen the response. Inflammation resolves, and tissue repair begins.

Chronic inflammation occurs when resolution fails. The triggers are varied: persistent infection, obesity (adipose tissue is a cytokine factory), gut dysbiosis, environmental toxins, chronic stress, and poor sleep. The result is a constant low-level activation of NF-κB and a steady drip of pro-inflammatory cytokines that remodel tissues over months and years (Bennett et al., 2018).

Why Standard Bloodwork Misses It

Standard CRP testing detects moderate-to-severe inflammation but often misses the low-grade chronic type. High-sensitivity CRP (hs-CRP) is more informative. Values between 1.0 and 3.0 mg/L indicate moderate systemic inflammation; above 3.0 suggests significant chronic inflammation. Most conventional panels don't include it unless specifically requested.

The Inflammatory Biomarker Panel

MarkerOptimal RangeElevated IndicatesUtility
hs-CRP<1.0 mg/LSystemic inflammation, cardiovascular riskHigh
IL-6<1.8 pg/mLActive inflammatory signalingHigh
TNF-α<8.1 pg/mLChronic immune activationModerate
ESR0–20 mm/hrGeneral inflammation (nonspecific)Moderate
Fibrinogen200–400 mg/dLVascular inflammation, clotting riskModerate
Homocysteine<10 μmol/LEndothelial inflammation, methylation issuesHigh

Key Anti-Inflammatory Peptides

Several peptides have demonstrated anti-inflammatory activity in preclinical and, in some cases, clinical research. They work through different mechanisms, target different parts of the inflammatory cascade, and vary in their evidence base. Here's what we know about each one.

Tissue Repair & Anti-Inflammatory

BPC-157 (Body Protection Compound)

A pentadecapeptide derived from human gastric juice, BPC-157 modulates inflammation through the nitric oxide system, downregulates TNF-α expression, and accelerates tissue repair across every tissue type tested. Its anti-inflammatory effects are secondary to its broader cytoprotective and healing properties, but they're well-documented across 100+ published studies. Unique among peptides for its gastric acid stability, making oral administration viable (Sikiric et al., 2018).

Targeted Anti-Inflammatory

KPV (Lysine-Proline-Valine)

A tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), KPV is one of the most directly anti-inflammatory peptides available. It inhibits NF-κB activation, reduces production of TNF-α, IL-1β, and IL-6, and has shown particular promise in gut inflammation models. A 2021 study demonstrated that KPV-loaded nanoparticles significantly reduced colonic inflammation in IBD mouse models (Dalmasso et al., 2021). It crosses cell membranes readily and accumulates in the nucleus where NF-κB operates.

Antimicrobial & Immunomodulatory

LL-37 (Cathelicidin)

The only human cathelicidin antimicrobial peptide, LL-37 plays a dual role in inflammation. It kills bacteria, fungi, and biofilms directly, while simultaneously modulating the inflammatory response to prevent excessive tissue damage. LL-37 neutralizes lipopolysaccharide (LPS), one of the most potent inflammatory triggers, and modulates dendritic cell and macrophage activity. In chronic infections where persistent bacterial presence drives ongoing inflammation, LL-37 addresses both the cause and the consequence (Kahlenberg & Kaplan, 2013).

Thymosin Alpha-1 and Immune Balance

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue. It's FDA-approved in over 30 countries for hepatitis B and C treatment, giving it a clinical pedigree most peptides lack.

Its anti-inflammatory effect comes through immune modulation rather than direct suppression. Tα1 enhances regulatory T cell function, promotes dendritic cell maturation, and shifts the immune response from a Th1/Th17 pro-inflammatory profile toward balanced Th1/Th2 signaling. In a 2020 study on COVID-19 patients, thymosin alpha-1 treatment was associated with reduced mortality and lower inflammatory markers in critically ill patients (Liu et al., 2020).

This makes Tα1 particularly relevant for autoimmune-driven inflammation, where the goal isn't to suppress immunity but to restore proper regulation.

Key Distinction

Most anti-inflammatory drugs suppress immune function broadly. Peptides like thymosin alpha-1 and KPV modulate specific signaling pathways, reducing pathological inflammation while preserving normal immune surveillance. This is the fundamental advantage of the peptide-based approach.


Mechanisms of Action: How Peptides Reduce Inflammation

Understanding how these peptides interact with inflammatory pathways helps explain why they can be more targeted than conventional anti-inflammatories. Each peptide hits the cascade at different points, which also explains why stacking multiple peptides can produce additive effects.

PeptidePrimary TargetMechanismEvidence Level
BPC-157NO system, VEGFModulates nitric oxide pathways; downregulates TNF-α; promotes angiogenesis and tissue repairStrong (100+ studies)
KPVNF-κB pathwayDirect NF-κB inhibition; reduces IL-1β, IL-6, TNF-α production; nuclear accumulationModerate (preclinical)
Thymosin α1T cell regulationEnhances Treg function; balances Th1/Th2 response; promotes dendritic cell maturationStrong (clinical trials)
LL-37LPS neutralizationBinds and neutralizes endotoxin; modulates macrophage polarization; antimicrobial clearanceModerate (mixed data)
BPC-157 + KPVMultiple pathwaysComplementary: tissue repair (BPC-157) plus direct NF-κB suppression (KPV)Theoretical + anecdotal

The NF-κB Pathway

NF-κB is the master switch of inflammatory gene expression. In its inactive state, it's held in the cytoplasm by inhibitory IκB proteins. When inflammatory signals arrive (TNF-α, IL-1, LPS, oxidative stress), IκB gets phosphorylated and degraded, freeing NF-κB to translocate to the nucleus and activate hundreds of pro-inflammatory genes.

KPV's primary mechanism involves entering the cell nucleus and directly inhibiting this NF-κB activation. Studies have shown it reduces IκB phosphorylation and subsequent NF-κB nuclear translocation in colonic epithelial cells (Brzoska et al., 2008). This is upstream of most drug targets, which typically block individual cytokines after they've already been produced.

The Nitric Oxide Connection

BPC-157's anti-inflammatory effects are inseparable from its interaction with the nitric oxide (NO) system. NO is a signaling molecule with paradoxical roles in inflammation: at low levels it's protective and anti-inflammatory; at high levels (produced by inducible nitric oxide synthase, or iNOS) it generates peroxynitrite and drives tissue damage.

BPC-157 appears to restore NO homeostasis rather than simply increasing or decreasing it. In animal models with NO system dysfunction (both excess and deficiency), BPC-157 normalized function in both directions (Sikiric et al., 2014). This bidirectional modulation is unusual in pharmacology and may explain BPC-157's broad protective effects.

Important Caveat

Most mechanistic data comes from animal models. While the pathways are conserved between species, human inflammatory conditions involve additional complexity. Peptide effects observed in mouse colitis models or rat wound healing don't automatically translate to equivalent effects in human autoimmune disease or metabolic inflammation.


Where Chronic Inflammation Does Its Damage

Systemic inflammation isn't one disease. It's a shared mechanism underlying dozens of conditions, each with its own tissue-specific presentation. Understanding which inflammatory pathways dominate in each condition helps match the right peptide to the right problem.

Cardiovascular

IL-6 and CRP drive endothelial dysfunction, plaque formation, and plaque instability. Inflammation is now considered the primary driver of atherosclerosis progression, not just cholesterol.

Gastrointestinal

TNF-α and NF-κB activation damage intestinal epithelium, increase permeability ("leaky gut"), and drive IBD flares. Gut inflammation often generates systemic effects through endotoxin translocation.

Neurological

Neuroinflammation (microglial activation, elevated CNS cytokines) is implicated in depression, cognitive decline, Alzheimer's, and Parkinson's. The blood-brain barrier becomes more permeable with systemic inflammation.

Metabolic

Adipose tissue produces IL-6 and TNF-α, creating a feed-forward loop: inflammation drives insulin resistance, insulin resistance promotes fat storage, more fat produces more cytokines. This is why weight loss reduces inflammatory markers independent of diet composition.

Joint and Connective Tissue

Matrix metalloproteinases (MMPs) activated by inflammatory cytokines degrade cartilage and collagen. Chronic joint inflammation doesn't just cause pain; it physically erodes the tissue structures. Peptides for joint health address this directly.


Anti-Inflammatory Peptide Protocols

Protocol design for inflammation reduction depends on the type, severity, and location of inflammation. A systemic protocol for metabolic inflammation looks different from a targeted gut inflammation approach. Below are evidence-informed starting points, not rigid prescriptions.

Safety First

These are research-based starting points, not medical prescriptions. Individual responses vary significantly. Start at the lower end of dosage ranges and titrate up based on response and biomarker changes. Work with a healthcare provider who understands peptide therapy.

ProtocolPeptide(s)Typical Dosage RangeDurationBest For
General Anti-InflammatoryBPC-157250–500 mcg/day (subcutaneous or oral)4–8 weeksBroad systemic inflammation
Gut-FocusedKPV + BPC-157KPV: 200–500 mcg/day; BPC-157: 250–500 mcg oral6–12 weeksIBD, leaky gut, food sensitivities
Immune RebalancingThymosin α11.6 mg 2–3x/week (subcutaneous)8–12 weeksAutoimmune-driven inflammation
Infection-DrivenLL-37 + Tα1LL-37: 50–100 mcg/day; Tα1: 1.6 mg 2x/week4–6 weeksChronic infection, biofilm-related
Aggressive StackBPC-157 + KPV + Tα1Combined dosing per individual peptide8–12 weeksSevere, multi-system inflammation

BPC-157 for Systemic Inflammation

BPC-157 is often the first peptide people reach for when addressing inflammation, and for good reason. Its safety profile across 100+ published studies shows zero serious adverse events. Its gastric acid stability means oral dosing is viable for gut-related inflammation.

For systemic anti-inflammatory effects, subcutaneous injection delivers more reliable bioavailability. The typical protocol is 250–500 mcg once or twice daily, injected subcutaneously near the area of concern or in the lower abdomen for systemic distribution. Most users run 4–8 week cycles.

BPC-157 doesn't just mask inflammation. It promotes actual tissue repair while modulating the inflammatory response. In NSAID-damaged gut tissue, BPC-157 reversed both the inflammation and the structural damage (Sikiric et al., 2018). This repair-while-resolving mechanism makes it particularly useful for conditions where ongoing tissue damage drives ongoing inflammation.

KPV for Gut and Systemic Inflammation

KPV is arguably the most targeted anti-inflammatory peptide currently available. Its direct NF-κB inhibition means it acts upstream of most conventional drugs, blocking the production of multiple inflammatory mediators simultaneously rather than neutralizing them one at a time after release.

For gut inflammation specifically, KPV has compelling preclinical data. In mouse models of colitis, oral KPV reduced colonic inflammation markers, improved histological scores, and promoted mucosal healing. Nanoparticle-encapsulated KPV showed even stronger effects due to improved stability and targeted delivery to inflamed colonic tissue (Dalmasso et al., 2021).

The KPV + BPC-157 combination is popular in the peptide community for gut inflammation because the two peptides hit different targets. KPV suppresses the inflammatory signaling while BPC-157 repairs the tissue damage. It's a logical pairing, though controlled human studies of the combination don't exist yet.


The Foundation: Lifestyle Factors That Drive Inflammation

Peptides are tools, not silver bullets. Running a KPV protocol while sleeping five hours a night, eating processed food, and staying sedentary is like bailing water without plugging the hole. The most effective anti-inflammatory strategy combines targeted peptide use with addressing the upstream drivers.

Research Finding

A 2019 meta-analysis in The Lancet found that poor diet quality alone accounted for more deaths globally than any other risk factor, including smoking. The mechanism is primarily inflammatory: ultra-processed foods elevate CRP, IL-6, and TNF-α in a dose-dependent manner (Afshin et al., 2019).

FactorInflammatory EffectImpact LevelActionable Target
Sleep DeprivationIncreases IL-6, TNF-α, CRP within 48 hoursVery High7–9 hours consistently
Ultra-Processed DietElevates CRP, drives endotoxemiaVery HighWhole foods, minimize seed oils
Visceral AdiposityAdipose tissue is an inflammatory organVery HighReduce body fat percentage
Sedentary BehaviorReduces anti-inflammatory myokine productionModerate150+ min/week moderate activity
Chronic StressCortisol dysregulation increases NF-κBModerateStress management practices
Gut DysbiosisEndotoxin translocation, barrier dysfunctionVery HighPrebiotic fiber, fermented foods

Exercise deserves special mention. Skeletal muscle is an endocrine organ that produces anti-inflammatory myokines (IL-6 from muscle has different downstream effects than IL-6 from adipose tissue). Regular exercise reduces hs-CRP by 20–30% independent of weight loss. Peptide protocols for athletes can complement training while addressing exercise-induced inflammation.


Monitoring Your Protocol

If you can't measure it, you can't manage it. Running an anti-inflammatory peptide protocol without baseline and follow-up bloodwork is guessing. You need objective data to know if your protocol is working.

Get a baseline inflammatory panel before starting any protocol. At minimum, this should include hs-CRP, fasting insulin, a complete metabolic panel, and ideally IL-6 and TNF-α if available. Retest at 6–8 weeks.

Practical Monitoring Schedule

Baseline bloodwork before starting. Retest at 6 weeks for fast-acting markers (hs-CRP, IL-6). Retest at 12 weeks for slower markers (HbA1c, fasting insulin). Track subjective symptoms (joint pain, energy, digestion, sleep quality) weekly using a simple 1–10 scale.

What Success Looks Like

A successful anti-inflammatory protocol should show measurable improvement in at least one objective biomarker within 6–8 weeks. hs-CRP dropping from 3.0+ to below 1.0 is a common and meaningful outcome. Subjectively, reduced joint stiffness, improved digestion, better sleep quality, and more stable energy are frequently reported.

If you're not seeing biomarker changes after 8 weeks, the issue is usually one of three things: the underlying inflammatory driver hasn't been addressed (diet, sleep, body composition), the peptide isn't reaching its target at adequate concentration (dosing or delivery route issue), or the inflammation is driven by a mechanism the selected peptide doesn't target well.


Stacking Peptides for Inflammation

Because different peptides target different parts of the inflammatory cascade, combining them can produce synergistic effects. The logic is straightforward: hit the problem from multiple angles simultaneously. For a broader overview of combining peptides, see the peptide stacking guide.

Gut Inflammation Stack

KPV (oral, 200–500 mcg/day) + BPC-157 (oral, 250–500 mcg 2x/day). KPV handles NF-κB suppression in colonic tissue; BPC-157 repairs epithelial damage and restores barrier function. Run 8–12 weeks.

Autoimmune Stack

Thymosin α1 (1.6 mg 2x/week subcutaneous) + BPC-157 (250 mcg/day subcutaneous). Tα1 rebalances immune regulation while BPC-157 addresses tissue damage from the autoimmune process. Run 12 weeks minimum.

Stacking Caution

More peptides doesn't always mean better results. Each peptide you add increases cost, injection burden, and the potential for unexpected interactions. Start with a single peptide targeting your primary issue. Add a second only if response is partial after 4–6 weeks. The triple stack (BPC-157 + KPV + Tα1) should be reserved for severe cases and ideally supervised by a practitioner experienced with peptide therapy.


Side Effects and Safety Considerations

Anti-inflammatory peptides generally have favorable safety profiles compared to conventional anti-inflammatory drugs. That said, "generally well-tolerated" doesn't mean "risk-free," and the absence of large-scale human safety trials for most of these compounds means our understanding of long-term effects is incomplete.

PeptideCommon Side EffectsRare/Theoretical ConcernsSafety Profile
BPC-157Mild nausea (oral), injection site rednessTheoretical concern re: tumor angiogenesis in those with existing cancerExcellent
KPVMild GI discomfort initiallyLimited long-term human dataGood (limited data)
Thymosin α1Injection site reaction, mild fatigueImmune flare in autoimmune conditions (paradoxical)Excellent (FDA-approved elsewhere)
LL-37Injection site pain, rednessPro-inflammatory at high doses; may worsen psoriasis or rosaceaModerate (dose-dependent)
LL-37 Dose Sensitivity

LL-37 has a particularly narrow therapeutic window. At appropriate doses, it reduces inflammation by neutralizing endotoxin and modulating immune cell behavior. At excessive doses, it can actually promote inflammation and tissue damage through mast cell degranulation and excessive neutrophil recruitment. This peptide requires more careful dosing than BPC-157 or KPV.

The most common risk with any peptide protocol isn't the peptide itself; it's sourcing quality. Contaminated, underdosed, or mislabeled products are a real problem in the unregulated peptide market. Always verify third-party testing, check Certificates of Analysis, and source from vendors with established reputations. See our guide on peptide vendor red flags for specifics.


Frequently Asked Questions

Can peptides replace NSAIDs for chronic pain?
For some people, yes, partially or fully. BPC-157 in particular has shown protective effects against NSAID-induced damage while providing its own anti-inflammatory and tissue-repair benefits. The key difference is that peptides work on different timescales. NSAIDs provide rapid symptom relief within hours; BPC-157 and KPV typically require days to weeks of consistent use before anti-inflammatory effects become noticeable. Many practitioners recommend a bridging approach: continue NSAIDs as needed for acute pain management while starting a peptide protocol, then gradually reduce NSAID use as the peptide effects build. This approach also allows BPC-157 to protect against NSAID-induced GI damage during the transition period.
How long does it take to see results from anti-inflammatory peptides?
It depends on the peptide, the route of administration, and the severity of inflammation. BPC-157 users often report subjective improvements (reduced pain, better digestion) within 1–2 weeks. Objective biomarker changes (hs-CRP reduction) typically appear at the 4–6 week mark. KPV for gut inflammation may show symptom improvement within 2–3 weeks. Thymosin alpha-1 for immune rebalancing is slower; meaningful immune panel changes often take 8–12 weeks. Set realistic expectations and commit to running the full protocol duration before concluding it isn't working.
Is it safe to stack anti-inflammatory peptides with conventional medications?
There's limited formal interaction data for most peptide combinations with pharmaceuticals, which is both the honest answer and the frustrating one. BPC-157 has been studied alongside NSAIDs and actually protects against their side effects, so that combination has some evidence behind it. For other peptide-drug combinations, the approach should be conservative: discuss any peptide use with your prescribing physician, especially if you're on immunosuppressants (which could interact unpredictably with thymosin alpha-1's immune-modulating effects), anticoagulants, or chemotherapy agents. The theoretical risk of combining BPC-157 with cancer treatment (given BPC-157's pro-angiogenic properties) is worth discussing with an oncologist specifically.
Do I need to cycle anti-inflammatory peptides?
Cycling recommendations vary by peptide. BPC-157 is commonly cycled 4–8 weeks on, 2–4 weeks off, though some practitioners use continuous low-dose protocols for chronic conditions. There's no published evidence of receptor desensitization with BPC-157. KPV is typically run in 8–12 week courses. Thymosin alpha-1, being closest to a conventional drug with its international approvals, has more established protocols: 1.6 mg two to three times weekly for 8–12 weeks, with breaks between courses. The peptide cycling guide covers this in more detail.
What's the best single peptide for someone new to anti-inflammatory protocols?
BPC-157 is the consensus starting point for most people. It has the deepest evidence base (100+ studies), the best-characterized safety profile (no serious adverse events across all published research), the broadest range of anti-inflammatory and healing effects, and the most flexible dosing options (oral for gut focus, injectable for systemic). It's also the most forgiving in terms of dosing precision. Start at 250 mcg once daily subcutaneously, or 500 mcg twice daily orally for gut-focused applications, and assess response over 4–6 weeks before considering adding a second peptide.
Can diet alone resolve chronic systemic inflammation?
In many cases, yes. Dietary modification is the single most impactful intervention for reducing systemic inflammation in people eating a standard Western diet. Eliminating ultra-processed foods, reducing refined sugar, increasing omega-3 intake, and eating a diverse range of plant fibers can reduce hs-CRP by 30–40% within 8–12 weeks. However, some inflammatory conditions have causes beyond diet: autoimmune disorders, chronic infections, environmental toxin exposure, genetic predispositions. In these cases, dietary optimization sets the foundation but may not fully resolve the problem. Peptides can address the residual inflammation that persists despite lifestyle optimization.
Are there any peptides that could worsen inflammation?
Yes. LL-37 at high doses can paradoxically increase inflammation through mast cell activation and excessive neutrophil recruitment. Some growth hormone secretagogues can increase IGF-1, which in certain contexts promotes inflammatory signaling. Even thymosin alpha-1, despite being an immune modulator, can occasionally trigger immune flares in people with autoimmune conditions as it upregulates immune function, not just rebalances it. This is why starting low, monitoring biomarkers, and working with a knowledgeable provider matters. The dose makes the medicine, and the context determines whether immune activation helps or hurts.

The Bottom Line

Summary

Peptides offer a targeted, mechanism-specific approach to reducing systemic inflammation that conventional drugs can't match. BPC-157, KPV, thymosin alpha-1, and LL-37 each address different nodes of the inflammatory cascade, from NF-κB activation to immune cell regulation to endotoxin neutralization. Combined with lifestyle optimization (sleep, diet, exercise, stress management), a well-designed peptide protocol can meaningfully reduce inflammatory biomarkers and improve quality of life.

The evidence base is real but incomplete. BPC-157 and thymosin alpha-1 have the strongest research support. KPV has compelling preclinical data but limited human studies. LL-37 is promising but requires careful dosing. None of these peptides are FDA-approved for inflammation treatment in the United States.

Start with the foundations: fix your sleep, clean up your diet, move your body, manage stress. Get baseline bloodwork. If inflammation persists despite lifestyle optimization, consider a targeted peptide protocol starting with BPC-157. Measure, adjust, and be patient. Chronic inflammation took years to develop; resolving it takes months, not days.

Medical Disclaimer
This article is for educational and informational purposes only. It is not medical advice. The peptides discussed are research compounds, and most are not FDA-approved for anti-inflammatory use in the United States. Thymosin alpha-1 is FDA-approved in over 30 countries but not in the US. Human clinical trial data is limited for most anti-inflammatory peptide applications. Consult a qualified healthcare provider before beginning any peptide protocol, especially if you have autoimmune conditions, are on immunosuppressive therapy, or have a history of cancer.

References

Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2018;9:1408. PubMed
Dalmasso G, Charrier-Hisamuddin L, Thu Nguyen H, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PubMed
Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects. Endocr Rev. 2008;29(5):581-602. PubMed
Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895-4901. PubMed
Liu Y, Pang Y, Hu Z, et al. Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis. 2020;71(16):2150-2157. PubMed
Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation-nature's way to efficiently respond to all types of challenges. Front Med. 2018;5:316. PubMed
Afshin A, Sur PJ, Fay KA, et al. Health effects of dietary risks in 195 countries, 1990-2017. Lancet. 2019;393(10184):1958-1972. PubMed
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PubMed

Related reading:

BPC-157: Complete Evidence-Based Guide  ·  KPV Peptide Guide  ·  Thymosin Alpha-1 Immune Guide  ·  LL-37 Antimicrobial Peptide Guide  ·  Peptides for Immune Health

For compound profiles and sourcing info, visit PeptideArc.